Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
A loss of -1.320% shows a downward development for Acadia Pharmaceuticals.
The stock is one of the favorites of our community with 28 Buy predictions and 1 Sell predictions.
With a target price of 31 € there is potential for a 121.03% increase which would mean more than doubling the current price of 14.03 € for Acadia Pharmaceuticals.
Our community identified positive and negative aspects for Acadia Pharmaceuticals stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Acadia Pharmaceuticals stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Acadia Pharmaceuticals | -1.320% | 3.163% | -10.183% | -39.547% | -50.616% | -21.208% | -36.596% |
Ironwood Pharmaceuticals | -1.800% | -6.034% | -26.351% | -46.040% | -46.569% | -44.388% | - |
Novocure Ltd | 4.840% | 5.435% | 80.694% | -68.865% | 49.492% | -86.241% | - |
Iovance Biotherapeutics Inc. | -2.500% | -2.040% | -15.122% | 31.330% | 18.110% | -40.117% | - |
Comments
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at HC Wainwright from $33.00 to $27.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Citigroup Inc. from $30.19 to $30.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $37.00 price target on the stock.
Show more
Ratings data for ACAD provided by MarketBeat